Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Испытание переходного ухода после выписки для пациентов с хроническим заболеванием печени (TLC)

3 ноября 2026 г. обновлено: Eric Orman, Indiana University

Рандомизированное исследование переходного ухода после выписки для пациентов с хроническим заболеванием печени

Patients with complications of advanced liver disease often have difficulties after hospital discharge that result in early hospital readmission. Poor outcomes for these patients during this transitional time could be improved through the use of innovative transitional care models. This proposal aims to examine the effect of a transitional care model, The Transitional Liver Clinic (TLC), in reducing hospital re-admissions, improving quality of life, and improving patient experience.

Обзор исследования

Статус

Рекрутинг

Вмешательство/лечение

Подробное описание

This study is a stepped-wedge randomized trial of 1,000 patients with advanced liver disease at four high-volume centers over 45 months (250 participants/site; <6 participants/site/month) to evaluate the efficacy of the Transitional Liver Clinic (TLC) compared to control.

In the stepped-wedge design, all sites provide usual care (control) during the initial 9-month enrollment interval. At each subsequent 9-month interval, one site is randomized via a computer-generated randomization scheme to crossover to implement the TLC, which will continue through the final interval where all sites will have implemented the TLC.

All sites enroll for the entire 45 months and thus contribute patients to both the control and TLC groups. There are an equal number of TLC and control intervals; thus approximately 500 patients will be in each group. Participant follow-up will occur by telephone at 30 and 90 days after discharge.

Тип исследования

Интервенционный

Регистрация (Оцененный)

1000

Фаза

  • Непригодный

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

  • Имя: Jake McCarty, BS
  • Номер телефона: 317-278-6305
  • Электронная почта: jacmccar@iu.edu

Учебное резервное копирование контактов

  • Имя: Regina Weber, BS
  • Номер телефона: 317-278-3584
  • Электронная почта: reginaw@iu.edu

Места учебы

    • Illinois
      • Chicago, Illinois, Соединенные Штаты, 60637
        • Рекрутинг
        • University of Chicago
        • Контакт:
    • Indiana
      • Indianapolis, Indiana, Соединенные Штаты, 46202
        • Рекрутинг
        • Indiana University Division of Gastroenterolgy and Hepatology
        • Контакт:
          • Regina Weber, BS, RRT
          • Номер телефона: 317-278-3584
          • Электронная почта: reginaw@iu.edu
        • Контакт:
          • Eric Orman, MD
          • Номер телефона: 317-278-1630
          • Электронная почта: esorman@iu.edu
        • Главный следователь:
          • Eric Orman, MD
    • Michigan
      • Ann Arbor, Michigan, Соединенные Штаты, 48109
        • Рекрутинг
        • University of Michigan
        • Контакт:
          • Elliott Tapper, MD
          • Номер телефона: 734- 936-9250
          • Электронная почта: etapper@umich.edu
    • Pennsylvania
      • Philadelphia, Pennsylvania, Соединенные Штаты, 19141
        • Рекрутинг
        • Albert Einstein Healthcare Network
        • Контакт:
          • Victor Navarro, MD
          • Номер телефона: 215-456-8242
          • Электронная почта: navarrov@einstein.edu

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  1. Male or female age ≥18

  2. Diagnosis of advanced liver disease, defined as either (must meet either a or b)

    1. cirrhosis based on (either i or ii):

      • biopsy
      • characteristic clinical, laboratory, and imaging findings
    2. acute alcoholic hepatitis, defined by NIAAA Alcoholic Hepatitis Consortia, as

      • onset of jaundice (serum bilirubin >3.0 mg/dL) in prior 8 weeks
      • consumption of >40 (female) or 60 (male) g alcohol/day for ≥6 months, with <60 days abstinence before jaundice onset,
      • AST>50 IU/L, AST/ALT>1.5, and both values <400 IU/L
      • liver biopsy confirmation in patients with confounding factors
  3. Has at least one of the following complications due to advanced liver disease occurring during hospitalization:

    1. ascites requiring diuretics or paracentesis
    2. hepatic encephalopathy requiring lactulose or rifaximin
    3. gastrointestinal bleeding due to portal hypertension
    4. jaundice
  4. Has planned discharge alive to home or a facility within 72 hours of informed consent

  5. Able and willing to provide informed consent

Exclusion Criteria:

  1. discharge under hospice
  2. listed for liver transplant with MELD-Na ≥ 35
  3. unable or unwilling to participate in post-discharge follow-up either in-person or virtually
  4. unable to speak or understand English and/or Spanish
  5. low hearing or communicative ability (examiner rated) that would interfere with interventions and outcome assessments
  6. lack of access to a telephone
  7. incarcerated
  8. concurrent enrollment in an interventional research study

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Назначение кроссовера
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Без вмешательства: Control group

Patients in the usual care arm will receive standard follow-up care from their usual providers based on recommendations made by inpatient providers at the time of discharge from the hospital.

Активный компаратор: Transitional Liver Clinic (TLC)

Enrolled patients discharged during the experimental TLC intervention implementation period will receive a phone call from TLC staff within 2 business days of discharge followed by an in-person or video telehealth clinic visit with a hepatology APP within 14 days of discharge. TLC staff will provide additional care based on individual patient needs during the 30-day transitional period.

Participants in this intervention receive additional attention from their Hepatology providers in terms of an additional call/telemedicine visit and more specific/additional attention from their Hepatology APP (advanced practice provider) based on individual patient needs

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
30-day hospital readmissions for patients hospitalized with complications of advanced liver disease
Временное ограничение: 30 days after discharge of initial hospitalization at which the participant was enrolled in the study.

The primary outcome, 30-day hospital readmission, is publicly reported by CMS, and is the benchmark measure in the Hospital Readmissions Reduction Program. It is therefore the most appropriate primary outcome.

30 days after discharge of initial hospitalization at which the participant was enrolled in the study.
Quality of life for patients hospitalized with complications of advanced liver disease via Promis 29+2 survey
Временное ограничение: 30 days after discharge of initial hospitalization at which the participant was enrolled in the study.

This measure includes 4 items in each of 7 health domains (physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, and pain interference) as well as a single item assessing pain intensity. Each domain is scored using a T-score metric in which 50 corresponds to the average for the US population with a standard deviation of 10, and a higher T-score represents more of the concept being measured. For example, higher fatigue scores indicate more fatigue (worse quality of life), while higher physical function scores represent better physical function (better quality of life).

30 days after discharge of initial hospitalization at which the participant was enrolled in the study.
Quality of life for patients hospitalized with complications of advanced liver disease via Promis 29+2 survey
Временное ограничение: 90 days after discharge of initial hospitalization at which the participant was enrolled in the study

This measure includes 4 items in each of 7 health domains (physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, and pain interference) as well as a single item assessing pain intensity. Each domain is scored using a T-score metric in which 50 corresponds to the average for the US population with a standard deviation of 10, and a higher T-score represents more of the concept being measured. For example, higher fatigue scores indicate more fatigue (worse quality of life), while higher physical function scores represent better physical function (better quality of life).

90 days after discharge of initial hospitalization at which the participant was enrolled in the study
Patient satisfaction for patients hospitalized with complications of advanced liver disease via the PSQ 18 questionnaire
Временное ограничение: 30 days after discharge of initial hospitalization at which the participant was enrolled in the study

The PSQ-18 consists of 18 items examining 7 dimensions of satisfaction with medical care: general satisfaction, technical quality, interpersonal manner, communication, financial aspects, time spent with doctor, and accessibility and convenience. Each item is scored with a 1 to 5 Likert scale and the individual item scores are averaged, with higher scores reflecting higher satisfaction.

30 days after discharge of initial hospitalization at which the participant was enrolled in the study
Patient satisfaction for patients hospitalized with complications of advanced liver disease via the PSQ 18 questionnaire
Временное ограничение: 90 days after discharge of initial hospitalization at which the participant was enrolled in the study

The PSQ-18 consists of 18 items examining 7 dimensions of satisfaction with medical care: general satisfaction, technical quality, interpersonal manner, communication, financial aspects, time spent with doctor, and accessibility and convenience. Each item is scored with a 1 to 5 Likert scale and the individual item scores are averaged, with higher scores reflecting higher satisfaction.

90 days after discharge of initial hospitalization at which the participant was enrolled in the study

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Number of ER visits
Временное ограничение: 30 days after discharge of initial hospitalization at which the participant was enrolled in the study and 90 days after discharge of initial hospitalization at which the participant was enrolled in the study

Recognizing the limitations on CMS data, the number of ER visits for each participant will be taken from the medical record and will be measured as a secondary outcome to provide a fuller picture of acute care utilization.

30 days after discharge of initial hospitalization at which the participant was enrolled in the study and 90 days after discharge of initial hospitalization at which the participant was enrolled in the study
90 day mortality
Временное ограничение: 90 days after discharge of initial hospitalization at which the participant was enrolled in the study.

Recognizing the limitations on CMS data, 90 day mortality will be measured as a secondary outcome to provide a fuller picture of acute care utilization.

90 days after discharge of initial hospitalization at which the participant was enrolled in the study.
Days alive out of the hospital
Временное ограничение: 90 days after discharge of initial hospitalization at which the participant was enrolled in the study.

Recognizing the limitations on CMS data, number of days alive out of the hospital will be measured as a secondary outcome to provide a fuller picture of acute care utilization.

90 days after discharge of initial hospitalization at which the participant was enrolled in the study.
Hospital readmissions
Временное ограничение: 30 days after discharge of initial hospitalization at which the participant was enrolled in the study and 90 days after discharge of initial hospitalization at which the participant was enrolled in the study

Participants will self report or data will be obtained from local institutional medical records the number of times, if any, they were admitted to the hospital during their time of participation in this study

30 days after discharge of initial hospitalization at which the participant was enrolled in the study and 90 days after discharge of initial hospitalization at which the participant was enrolled in the study

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Следователи

  • Главный следователь: Eric Orman, MD, Indiana University

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

1 сентября 2023 г.

Первичное завершение (Оцененный)

30 июня 2028 г.

Завершение исследования (Оцененный)

30 июня 2028 г.

Даты регистрации исследования

Первый отправленный

18 января 2023 г.

Впервые представлено, что соответствует критериям контроля качества

8 февраля 2023 г.

Первый опубликованный (Действительный)

17 февраля 2023 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

6 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

3 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • TLC
  • R01DK132390 (Грант/контракт NIH США)

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕТ

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться